Breast Cancer Coverage from Every Angle

FDA Approves Trastuzumab Biosimilar for Treatment of Advanced Breast Cancer

By: Sarah Jackson
Posted: Tuesday, January 22, 2019

On January 18, the U.S. Food and Drug Administration (FDA) approved trastuzumab-dttb (Ontruzant), a biosimilar referencing trastuzumab, across all eligible indications—namely, adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease.

Trastuzumab-dttb, the third trastuzumab biosimilar to be approved by the FDA, was also approved by the European Commission in November 2017. It has since been launched in a growing number of European countries.

Trastuzumab-dttb is indicated for the adjuvant treatment of HER2-overexpressing node-positive or node-negative (estrogen receptor–/progesterone receptor–negative or with one high-risk feature) breast cancer as part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; with docetaxel and carboplatin; or as a single agent after multimodality anthracycline-based therapy.

In addition, trastuzumab-dttb is indicated in combination with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer; as a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease; and in combination with cisplatin and capecitabine or fluorouracil for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.